At present, a variety of techniques are used for pretransplant screening of sera for HLA specifi c antibodies, and determination of antibody specifi cities. While CDC remains the gold standard, antibody binding assays are gaining popularity. To facilitate antibody screening we recently developed a panel of single HLA class I antigen expressing lines (SAL), and tested the expression with human monoclonal HLA antibodies (HuMAbs) by fl ow cytometry (FCM). In another FCM based assay, (FlowPRA from One Lambda), the full sets of HLA-A,B,C antigens derived from cell lines are immobilized on beads, suitable for the detection of serum HLA antibodies. In this study we compared the immunological integrity of HLA class I on the SAL and on fl ow PRA beads, as tested by FCM, with that on PBLs, as tested by CDC, using a set of 76 HuMAbs. We considered HuMAb specifi city returned by CDC testing against large panels (n>240) of PBLs as standard. Only those antigens (n=21) present in our SAL panel (for A-locus: n=7, B-locus n=14) were considered. The size of the HuMAbs set ensures detection of multiple epitopes on each antigen. The two new binding methods return the CDC defi ned specifi cities faithfully. Because in both new methods the numbers of extra reactions surpass the numbers of false negatives, they both provide increased sensitivity compared to CDC. In conclusion, binding methods constitute an attractive alternative for antibody screening, and particularly assays based on single antigen format defi ne serum specifi cities with greater accuracy. The relevance of binding antibodies in transplantation still needs to be established.
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PREDICTING PATERNAL IMMUNIZATION IN WOMEN WITH RECURRENT SPONTANEOUS ABORTIONS (RSA): HLAMATCHMAKER ASSESSMENT OF AMINO ACID MISMATCHES
Tirza Klein, Don Kristt, Moshe Israeli and Rene J. Duquesnoy.
Laboratory of Histocompatibility and Immunogenetics, Rabin Medical Center, Petach Tikvah, Israel.
Treatment of women with immunologically mediated RSA involves sensitization to the HLA antigens on her mate's lymphocytes. When seroconversion occurs, future pregnancies are often successful. At present there is no effective means of predicting those unlikely to be effectively immunized. We were interested in using the HLAMatchmaker, which predicts the likelihood of HLA compatibility despite apparent HLA mismatches. The basis for the algorithm is the assumption that some HLA mismatched couples may still be immunologically "matched" for amino acid triplet sequences located at immunogenic, antibody accessible epitopic sites on HLA antigen molecules. The aim of this study was to investigate whether the extent of triplet mismatching was correlated with the immunogenicity of the male. 92 couples participated in the study with a history of RSA. They were divided into 5 groups, numbered 1 to 5, according to the number of treatments needed to reach serum conversion. HLA class I amino acid triplet mismatches, mmT, between the male and female were determined using HLAMatchmaker. We found an inverse correlation between the number of mmT and the number of unsuccessful immunization treatments. Statistically signifi cant differences were observed between Groups 1 and 3 and between Group 1 and 5 (Student's T-test, p<0.04). Conclusion: The data suggest that the fewer the number of mismatched triplets in a couple, the higher the likelihood of immunization failure. Although HLAMatchmaker analysis may have a role in the assessment process other factors still need to be uncovered to achieve a more precise risk assessment. This work present a clinical case of presensitization of a patient and methods to analyze it which may no reach a correct detection. A 45-yearold-woman with end-stage renal disease was transplanted and apparently not sensitized to HLA antigens, with PRA=0% by CDC assay without previous transfusions and transplants. Before transplantation, crossmatch (CM) by CDC was negative. On the 6th day, the patient presented facts that were strongly suggestive of acute humoral rejection.Postransplant CM by CDC was positive and also CDC and FlowPRATM screening, detecting an anti-A2 antibody (donors typing had A2) in high title. We performed FlowPRA screening in pretransplant serum and resulted negative confi rming the pretransplant CDC screening. We also performed luminex technology and found in the pretransplant serum anti-A2 and -B7 antibodies in low title, which had no been detected by CDC and FlowPRA. Thus, we performed familiar typing of patients sons (her last pregnancy was 17-year ago). Sons presented A2 and B7 mismatches with their mother and CDC CMs of the patients pretransplant serum and the sons T cells CDC were negative whereas the postransplant were positive. Thus, sensitization was caused by previous exposure to paternal HLA antigens and the problem was no detect prospectively these pretransplant antibodies by CDC and FlowPRA. These were retrospectively detected by luminex technology when the patient had graft loss. In conclusion, the different metodologies for HLA sensitization detection could have discrepant results. At the moment, luminex technology seem to be the most sensitive and safe for antibody detection. RANTES, a member of C-C chemokine, is potent eosinophil, monocyte, basophils and lymphocyte chemoattractant at site of infl ammation with particular preference for CD45RO+ T cells and eosinophils. Recent studies revealed that a mutation at -403 in the promoter may have a signifi cance for atopic dermatitis, bronquial asthma, sarcoidosis, rheumatoid arthritis and HIV infection. Our objetive was to investigate RANTES polymorphism in the different types of bronquial asthma. In this study, 181 asthmatic patients with intrinsic (n=57) and extrinsic (n=124) asthma and 100 controls were analysed. Sequence oligonucleotide primers were utilized with PCR to amplify a 135 base pairs segment of the RANTES 5-fl anking region between nucleotide -513 and -378 relative to the major transcriptional start site. A G base at the 3 end of the reverse was mutated from a C to introduce an enzyme site for MaeIII. PCR products were digested with 2 U of MaeIII (Roche Diagnostics, Mannheim, Germany) at 37C for 2 h, and visualized on agarose gels (low melting point, Sigma). Of the 124 extrinsic asthmatic patients, 5 had the AA genotype (4.1%), 34 the GA type (27.4%), and 85GG type (68.5%). The G allele frequency was 82.2% and the A allele frequency 17.7%. Of the 57 intrinsic asthmatic patients, 2 were type AA (1.6%), 19 were GA (33.3%), and 36 were GG (63.1%). The G allele frequency was 79.8% and the A allele 20.1%. No signifi cant differences in the genotype distribution and in the allele frequencies were observed between the intrinsic and extrinsic asthmatic patients and healthy control subjects (p>0.05). In conclusion, RANTES gene polymorphism does not seem to infl uence the different types of bronquial asthma.
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SPECIFICATION OF NON-COMPLEMENT BINDING ANTI-HLA ALLOANTIBODIES
Marie-Luise Arnold1, Thorsten Zacher, Joachim R. Kalden1; Ilias I.N. Doxiadis, Bernd M. Spriewald1 1Institute for Clinical Immunology, Department of Internal Medicine III, University of Erlangen-Nuremberg, Germany.
Introduction: Pre-existing anti-human leukocyte antigen (HLA) antibodies (Ab) have been associated with reduced survival of renal grafts. Whether various Ab-subclasses have a differential impact on graft survival is still under debate. The aim of this study was to investigate the distribution of immunoglobulin (Ig) subclasses among anti-HLA alloimmunised patients awaiting kidney re-transplantation (Tx). Study design: We developed a detection method by modifying an ELISA system using different conjugated-secondary-Ab subclasses against IgG1-4. Sera from 102 patients were analysed for anti-HLA class I and class II Abs by a complement dependent cytotoxicity test and by ELISA test. Subsequently, the presence of the various IgG-subclasses in the Abs were examined by our newly generated ELISA. Results: The non-complement binding IgG2 subclasse were found in 23 (22.6%) and the IgG4 in 16 (15.7%) sera. Afterwards the IgG2 and/or IgG4-Ab positive samples (25) were tested by an extended, similarly modifi ed ELISA which recognises anti-HLA Ab specifi cities. In the IgG2 positive group, anti-donor-specifi c Abs were determined in 89.5% (17/19) against HLA-class I and in 68.8% (11/16) against HLA-class II. In the IgG4 positive group, anti-donor-specifi c Abs were defi ned in 83.3% (5/6) against HLA-class I and in 85.7% (12/14) against HLA-class II. Conclusion: The high frequency of non-complement binding Abs in transplanted patients suggests an involvement of these Abs in donor specifi c rejection by a non-classical pathway. These results underline the importance of a reliable assay that is able to detect the specifi city of noncomplement binding anti-HLA Abs in patients awaiting re-Tx.
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RE-EVALUATION OF LOW PRA VALUE AS ALLOCATION PARAMETER OF CADAVERIC KIDNEY IN SLOVENIAN PATIENTS ON THE ET WAITING LIST
B Vidan-Jeras*,N Pisec*,AM Vrbic*,MD Witvliet**,M Jeras*,IIN Doxiadis** *Blood Transfusion Center of Slovenia, Ljubljana, **Eurotransplant Reference Lab., LUMC, Leiden
In kidney transplantation, screening for panel reactivere antibodies (PRA) permits a prediction of the pre-transplant crossmatch, aids in its interpretation and allows a more effi cient approach to matching. In the Eurotransplant (ET), PRA value is a parameter of kidney allocation. A patient is considered immunised when PRA value higher than 5% is determined in his sera. The CDC test conventionally used for determination of PRA may result in a false positive outcome due to non-HLA antibodies as well as in a false negative outcome due to non-complement fi xing antibodies. All current sera from Slovenian patients on the ET waiting list were tested by ELISA (One Lambda)and CDC using local (CDC1) and commercial (Biotest) complement (CDC2). We found 100 out of 126 sera negative for HLA class I and class II antibodies when tested by ELISA. In 13 sera negative by ELISA low PRA (from 5% to 10%) was determined by CDC1. In only 5 of these sera low PRA values were ascertained also by CDC2.Addionally, low PRA values were determined using CDC2 in 6 distinct CDC1 and ELISA negative sera. In depth analysis of reactions of sera showing low PRA by CDC and comparison of scores obtained with both complements revealed high discrepancy, giving the advantage to ELISA test. These results highlighted the importance of using a combination of techniques when considering a screening strategy and the need to re-evaluate low PRA values obtained by CDC as allocation parameter of cadaveric kidney. Detection of anti HLA antibodies (Ab) in the post transplant setting can be performed either by anti HLA Ab identifi cation or by cross-matching (CM) between recipient sera to graft cells. In this study we used an ELISA CM assay specifi c to IgG HLA class I and class II Ab: Transplant Monitoring System (GTI). We show how the ELISA CM assay associated with the HLA Ab high defi nition identifi cation ELISA assay (One Lambda) allowed us to support the diagnosis of acute humoral rejection in a clinical case of a patient exhibiting an acute graft failure ten days after kidney transplantation. HLA Ab were identifi ed in patient sera collected before and after transplantation by LCT, ELISA LAT M and LAT-HD. ELISA CM was performed to donor on the same sera. Patient's and donor's HLA typing were respectively HLA 2, A32, B51, B61, DR13, DR7 and HLA A2, A24, B60, DR7. Our ELISA CM results showed that the patient developed donor specifi c HLA class I Ab detected the day of rejection diagnosis and weakly on a serum drawn out fi ve years ago. ELISA LAT-HD identifi ed an anti HLA B60 Ab to the graft. The patient was fi rstly immunised to HLA B7 and cross reactive group, including B60 undetected by LCT, fi ve years before transplantation. Since the graft was B60 homozygous, the anti B60 Ab production was reactivated leading to acute rejection. Post transplantation ELISA cross-matching associated with sensitive and specifi c anti HLA identifi cation assay are very useful tests for post transplantation follow up. Investigation of the HLA antibody status of patients refractory to random platelet transfusion requires the rapid determination of antibody specifi city to allow the prompt provision of HLA compatible platelets. Using the lymphocytotoxicity (LCT) test it can take at least 2 weeks to defi ne the antibody profi le of highly sensitised patients (HSP). In this study, 2 methods for the defi nition of HLA specifi c antibodies and acceptable mismatches using Luminex technology were evaluated. 18 HSP with a PRA of greater than 75%, as defi ned by the LCT using an initial panel of 30 cell donors, were tested by the LABScreen PRA Class I kit in which each bead population is coated with HLA antigens derived from an individual donor and the LABScreen single antigen beads (SAB). The LABScreen PRA kit detected additional specifi cities to those defi ned by LCT, in only 7/18 (39%) of HSP. However, the SAB detected additional antibody specifi cities in 17/18 (94%) of the patients tested. In 7 patients, transfusion of platelets bearing antigens to which antibodies were only detected by SAB, resulted in a poor increment i.e. <10. The SAB can be used to rapidly defi ne clinically signifi cant HLA antibody specifi cities in HSP receiving platelet transfusions, without the need for extensive screening panels
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THE USE OF LABSCREEN SINGLE ANTIGEN BEADS FOR
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LUMINEX DETECTS ANTIBODIES TO HLA ANTIGENS UNDETECTABLE BY CDC Manuela S.Monteiro1, Jose F.Teixeira1, G.Oliveira2, A.Castro Henriques3, E.Osorio1, H.Alves,1 ; 1Centro Histocompatibilidade do Norte, Porto, Portugal ; 2H.S.Joao ; 3H.G.Santo Antonio Introduction:It is known that anti-HLA Antibodies (Ab) are linked to the process of chronic and acute rejection in kidney allotransplant (TX). It is therefore important to know the Ab profi le of the kidney graft recipients. Materials and Methods:Our population consisting of 623 patients on waiting list for kidney TX was studied by CDC and Luminex LifeScreen and LifeMatch ID class I and II (Orchid Diagnostics). Results: We verifi ed that 36 patients (5.7%) repeatedly had a negative PRA by CDC and a positive LifeScreen. for class I and/or II (17 patients were to be transplanted for the 1st time; 18 for the 2nd time; and 1 for the 3rd time). Using LifeScreen we verifi ed that 9 patients had class I Ab, 17 had class I and II, and only 10 patients had class II Ab.
Out of the 17 patients to be considered for a fi rst TX with Ab, 16 were female (100% had had one or more pregnancies and/or had been submitted to blood transfusion(s)) and 1 was male (2 transfusion). Out of the 19 patients on the 2nd/3rd TX waiting list, 18 had anti-donor Ab (94.7%) identifi ed by LifeMatch ID. Conclusions: 1-The use of this new, simple, and sensitive technology has allowed the Ab' profi ling of these patients before a kidney TX.
2-The results obtained lead to the non-consideration of these patients for TX and do not allow their selection for crossmatch whenever the donor shows the respective Ag. 3-Nowadays we regard CDC as a useful technique, but it should not be the only technique used for Ab' identifi cation and for crossmatch, even in a 1st TX.
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CHARACTERIZATION OF HLA-SPECIFIC ANTIBODIES IN PATIENTS AWAITING RENAL TRANSPLANTATION USING SINGLE ANTIGEN COATED COLOR-CODED BEADS
F. Heinemann (1), N. Lachmann (2), C. Schoenemann (2) and H. GrosseWilde (1) Institute of Immunology, University Hospital of Essen, Germany (1) and Institute of Transfusion Medicine, Charite, Humboldt University Berlin, Germany (2) The identifi cation of specifi cities in antibody positive patient's sera is of central importance in renal transplantation. Recently, sensitive ELISA and FC based techniques have been introduced for HLA antibody screening. The characterization, however, of HLA specifi cities in sera that either contain very low antibody titers or were procured from highly immunized patients (>85% PRA) still is a problem. Therefore, color-coded beads coated with single recombinant HLA molecules offer a new technical approach. We investigated in our study sera from clearly immunized patients (10-85% PRA, n= 29) and sera that revealed borderline positive results when analysed by ELISA technique (n=18) using single antigen beads for FC (FlowPRA.HD) and Luminex (LABScreen.HD) from One Lambda Inc. HLA antibody status was previously determined using ELISA (One Lambda) and CDC assays. The patient's immunizing events were included in the interpretation of the HLA specifi city analysis. Our analyses revealed 23 (79%) of the sera from clearly immunized patients with concordant HLA-specifi cities determined by FlowPRA.HD vs. 16 (55%) with the LABScreen.HD assay when compared with the CDC results, whereas 7 (39%) of the low titered sera had concordant specifi cities when analyzed by either FlowPRA.HD or LABScreen.HD in comparison with the CDC. The LABScreen.HD single antigen methodology seems to be a promising alternative for HLA antibody defi nition of sera with very low and high antibody titers. However, the characterization of low titered sera with FlowPRA.HD was complicated due to insuffi cient discrimination between positive and negative reactions. The accurate identifi cation of HLA antibody specifi cities is essential in a renaltransplant programme to reduce the incidence of positive crossmatches, which prolong cold ischaemia times. In our laboratory, antibody detection is routinely performed using CDC and ELISA whilst CDC and fl ow cytometry crossmatches are performed for all renal transplants. In the period July to December 2003, 4 positive fl ow crossmatches occurred which were unexplained by our current antibody detection methods.
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Positive fl ow crossmatches were retrospectively investigated using luminex antibody detection (One Lambda, GTI) and found to be due to previously undetected HLA class I antibodies. In 2 patients, anti-A2 was detected in addition to specifi cities previously identifi ed by CDC and ELISA. Anti-B64 was found in patient 3, most likely raised by sensitisation to paternal HLA-B8 during pregnancy and subsequent production of crossreactive antibodies. Finally, anti-A11 was detected in patient 4. All the antibodies described above correlated with mismatched donor antigens on the offered kidneys.
These data demonstrate luminex technology has a level of sensitivity comparable to fl ow cytometry. Antibody specifi cities identifi ed by luminex and previously undetected by ELISA, have resulted in positive fl ow crossmatches. The additional specifi cities detected by luminex can be accounted for by previous sensitisation events and therefore should be considered clinically relevant.
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FALSE NEGATIVE RESULTS IN THE "REAL WORLD" OF PATIENT SERA SCREENING BY ELISA TESTS Daniela Contini-Duarte, Cleusa Schafhauser, Karina Omairi, Carolina Kneib, Sandra M Ferreira, Josemere H Lima, Vera J Chicora, Marco A Costa, Maria M Okoinski, Luciane Kaminski and Cristina von Glehn. Immunogenetics Laboratory -Health Alliance-PUCPR (imunog@rla13.pucpr.br)
The aim of this study was to evaluate the sensitivity of the LAT-M screening versus LAT-1240/1288 tests. Methods: 165 and 186 sera waiting list patient to transplant were tested for class I and II screening, respectively. All sera were tested for LAT-M and LAT-1240 and/or 1288 (LAT-Sp). We used One Lambda's technical protocol for ELISA tests. Results: Among 165 sera were tested in the LAT-M, from these 116 were positive, 23 were at gray zone (GZ) and 26 presented class I negative and class II positive. From 116 LAT-M positive samples, 8 were negative in LAT-Sp. The 23 at GZ, 6 were negative and 17 positive in LAT-Sp. To class I negative samples (23), 7 were positive for LAT-Sp, with %PRA that vary of 11% to 43%, also with the characterization of antibodies. To class II, the 186 sera tested in LAT-M, 153 were positive, 14 were at GZ and 19 were negative to class II and class I positive. From 153 positive sera 12 were negative. In the GZ (19) 4 sera were negative and 10 were positive. To the negative samples, 6 negative sera in LAT-M were positive for LAT-Sp, with % PRA that vary of 6.3% to 85%.
Discussion & Conclusion:
The comparison of the results between LAT-M and LAT-1240/1288 showed that: highs sI values doesn't correspond to high %PRA values, because the LAT-M test only measures the antibodies title, independently the antibodies "universe", than it is not possible to establish dilutions "rules" for LAT-1240/1288 tests based on LAT-M values. Among 165 sera LAT-M positive for class I and negative for class II and 186 sera LAT-M positive for class II and negative to class I, we found 4.8% (class I) and 6.4% (class II) false positive sera and 5% (class I) and 3.5% (class II) false negative sera, respectively. Our results showed that: it is necessary to fi x others parameters for LAT-M cut off's calculation, because we can't have false negative results in one screening sera test which the use is identify positive samples, and only this will be analyze by specifi cs tests.
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THE USE OF IMMUNOMAGNETIC BEADS FOR ISOLATING CELLS: BE STRICT WITH THE "DETAILS" AND ENJOY YOUR RESULTS!
Carolina Kneib, Karina Omairi, Josemere H Lima, Daniela Contini-Duarte, Sandra M Ferreira, Madalena Okoinski, Claudia H Takemura, Gisele C Possebon, Helena B Cazarotte, Ivy N Vieira and Cristina von Glehn. Immunogenetics Laboratory Health Alliance-PUCPR, imunog@rla13.pucpr.br.
The purpose of this study is to set up an intern QA to T and B cell IMB isolation, for guarantee the CM success in our laboratory. The culture medium which used was salt balanced solution (SBS) with FBS 10% at 25C for T and 4C for B cells. The blood samples were collected with ACD, spleen/lymph nodes were preserve only with SBS at 4C. Different from the manufacture protocol for B cell we didn't use PBS-citrate. The IMB used was fl uorobeads (FB1 and FB2). The lots tested were 069/070/074/076 for FB1, and 190/197/199/201 for FB2. The cells viability was analyzed independent if they were from recipients or donors. We analyzed the results of 1025 cell isolations, 916 from blood, 40 nodes and 69 spleens. The data were analyzed based on the time in the magnetic separator. The room temperature has to be 22-25C and the SBS temperature at 22-25C for T and 4C for B, the wash steps and homogenization carefully done, all in the same manner, because these details have a great infl uence on the cell viability. First, we compared the IMB lots and different results were found between them: For FB1: 96% for lot 069, 94% for lot 070, 93% for 074, 97% for lot 076, and for FB2, 96% for lot 190, 91% for lot 197, 82% for lot 199, 92% for lot 201. Second, the performance of the two technicians that are responsible for the technique came to the following: 95% to T cell and 94% to B cell for the fi rst, 95% to T cell and 89% to B cell for the second technician. The fi nal average is 95% and 91% to T and B cells, respectively. Third, the performance of the fi rst two technicians was compared to all the others, which eventually did IMB cell isolation; we observed a difference between them and others (95% X 92% to T and 91% X 87% to B cells). Conclusion: The IMB cell isolation is one of the fastest methods to obtain purity cells populations, but the viability of these cells depend on "small" details and the technician's experience and knowledge of the procedure, therefore the intern laboratory QA, 95% for T and 91% for B, is the average between the technician 1 and 2 performance. Aim: The aim of this study was to see if there was a relation between the appearance of IgG class anti-HLA antibodies post-transplantation in sera of kidney allograft recipients and graft function.
Methods: HLA profi les of donors and recipients were determined by the complement dependent microcytotoxicity assay and by DNA typing (SSP).The presence of anti-HLA antibodies in sera of 48 kidney allograft recipients prior to transplantation, and at different time intervals post-transplantation was determined by an Enzyme Linked Immunosorbent Assay.
Results: Antibodies were not detected in Forty one of the 48 patients. Five of the 41 antibody-negative patients had at least one rejection episode. Antidonor HLA class I antibodies were detected post-transplantation in the sera of 1 patient who experienced a rejection episode. Another patient who experienced a rejection episode had high levels of anti-HLA class II antibodies, the specifi city of which was not identifi ed. Anti-non-donor HLA class I antibodies were detected in the remaining 5 patients, all of who maintained normal graft function.
Conclusion: An immunological cause for rejection episodes in the 5 antibody-negative patients could not be confi rmed. Anti-donor HLA class I antibodies in 1 patient and anti-HLA class II antibodies in an other patient post-transplantation might have been the cause of rejection episodes in these 2 cases. Based on recent reports, the appearance of anti-non-donor HLA antibodies post-transplantation might be an indicator for future rejection of the allograft.
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COMPARISON OF THE HUMORAL RESPONSE AGAINST HLA CLASSES I AND II ANTIGENS IN CELLULAR AND DECELLULARIZED CRYOPRESERVED CARDIAC VALVE ALLOGRAFTS IN THE FIRST 30 DAYS AFTER THE IMPLANTATION
Daniela Contini-Duarte*; Carolina Kneib*, Karina Omairi*, Ivy N Vieira*, Vanessa S Paladino*, Marco A Costa*, Joao Gabriel R Mendonca*, Marisa B Costa***, Claudinei Colatusso**, Sergio A V Lopes**, Pascal Dohmen****, Wolfgang Konertz****; Francisco D A Costa** and Cristina von Glehn* -*Tissue Typing Laboratory and **Department of Cardiac Surgery and ***Homograft Tissue Bank -Health Alliance-PUCPR and ****Humboldt University Berlin
In this preliminary report we examined the HLA antibodies response in the fi rst 30 days after implantation of cellular cryiopreserved allografts (Group A -6 patients) and decellularized cryiopreserved allografts (Group B -8 patients). Methods: The recipient sera were assayed for anti HLA (class I and II) antibody using an ELISA test (Lambda LAT-M). This kind of test only detected IgG. The sera were collected before the operation, in PO days 5, 10 and 30 in both groups. Results: Preoperatively, all patients were anti-HLA class I/II antibody negative. In group A, all samples were negative for HLA class I and II at day's 5 and 10 PO, however, 3 patients became positive for both class I and II at 30 days. In Group B, we observed positive response only for HLA class I in one patient at day 5 and in two patients at 10 and 30 days, respectively. In no occasion we could observe any response to HLA class II in this group.Conclusion: This preliminary study demonstrates that both cellular and decellularized allografts were immunogenic; however, the type and timing of these responses were different, possibly related to graft preparation methods. Further evaluation is needed to determine the impact of these differences on clinical behavior of these grafts.
